MarketPulse

FDA approvals

3 articles
BenzingaBenzinga··Vandana Singh

AstraZeneca Beats Q1 Estimates on Cancer Drug Surge, Yet Shares Retreat

AstraZeneca ($AZN) reported Q1 revenue of $15.29B, up 13% YoY, with oncology surging 20%. Shares fell 2.30% despite beating estimates.
AZNearningsrevenue growth
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly Edges Vertex as Superior Growth Pick Amid GLP-1 Boom

Eli Lilly ($LLY) outpaces Vertex ($VERX) as superior growth stock pick with Zepbound dominance in booming weight-loss market and stronger financials at comparable valuations.
LLYVRTXcystic fibrosispharmaceutical growth
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Lantheus Shifts Strategy, Posts $1.54B in 2025 Revenue Amid Pipeline Expansion

Lantheus posted $1.54B in 2025 revenue but faces Q4 headwinds. The company plans to refocus on PET diagnostics while exploring options for radiotherapy assets, expecting four FDA approvals in 2026.
LNTHearningsacquisitions